Xceleron announces new board and executive appointments
14 June 2011
York-based Xceleron, a leader in accelerating drug development
using ultra-sensitive bioanalytical analyses, has announced that Dr
David Roblin has been appointed to its Board of Directors in a
non-Executive capacity and Dr Stuart Best has joined the company as
Senior Director Operations.
Dr Roblin joins the Xceleron Board from Pfizer Global R&D where
he was most recently Senior Vice President R&D, Research Head and
Site Director. He has an outstanding track record of product
innovation and leadership, bringing about business and technology
changes to improve productivity in research and development. His
experience crosses therapeutic areas within the spectrum of small
and large molecule R&D.
Dr Best joins Xceleron from Merck, Scotland where he was Head of
Bioanalysis. Dr Best’s career has been distinguished by his
leadership in applying progressively sophisticated analytical
technologies to this expanding and complex area of chemistry. Prior
to Merck, Dr Best developed his reputation as an authority in the
use of mass spectrometry in bioanalysis at Charles River (Inveresk).
Xceleron CEO Michael Butler commented: “These two new additions
to our team come at an exciting time for the Company. In the last
two years Xceleron has more than doubled its ‘top 20’ pharmaceutical
clients and is increasingly being asked to provide supporting data
for critical events and regulatory submissions. David Roblin is a
hugely valuable addition to our Board, he understands the nature of
the challenge that large pharma companies face and will help us to
continue to meet that need.
Stuart Best is a seasoned pharma manager with a deep
understanding of pharmaceutical clients’ operational needs and
recognised expertise in the application of novel analytical
technologies in drug regulatory development.”
Dr Roblin commented,”This is a unique opportunity with Xceleron.
The pharmaceutical industry urgently needs innovative solutions and
Xceleron’s ability to increase R&D productivity is creating a lot of
client interest. The crucial benefits that we enable are reduction
in cycle time from lead optimization to Phase 1, reduced development
costs in Phases 1 and 2 and a shift in attrition from Phase 2 to
Phase 1, making success in Phase 2 more likely.”